A Study of LY3435151 in Participants With Solid Tumours

Titre officiel

A Phase 1a/1b Study of LY3435151 Administered to Patients With Advanced Solid Tumours

Sommaire:

The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumours.

Description de l'essai

Primary Outcome:

• Number of Participants with LY3435151 Dose-Limiting Toxicities (DLTs)

• Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3435151
• PK: Cmax of LY3435151 in Combination with Pembrolizumab
• Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR)
• Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, and Stable Disease
• Duration of Response (DoR)
• Time to Response (TTR)
• Progression Free Survival (PFS)

Voir cet essai sur ClinicalTrials.gov